Methylene Blue

Methylene blue is a synthetic compound with over a century of pharmaceutical history, FDA-approved at higher doses as a treatment for methemoglobinemia. At low doses -- typically in the range of 0.5 to 4 mg/kg or lower fixed doses as guided by a provider -- methylene blue functions as an alternative electron carrier in the mitochondrial electron transport chain and has generated significant interest among researchers and longevity-focused clinicians for its proposed effects on cellular energy metabolism and neuroprotection.

Within mitochondria, methylene blue can accept electrons from NADH and shuttle them directly to cytochrome c, effectively functioning as a bypass around dysfunctional segments of the electron transport chain. This property has led to preclinical research exploring its potential role in conditions associated with mitochondrial dysfunction and oxidative stress. Additionally, methylene blue has demonstrated antioxidant properties in certain cellular environments, though at higher doses it can paradoxically act as a pro-oxidant -- a dose-dependent duality that underscores the importance of precise low-dose formulations and provider oversight.

Low-dose methylene blue is taken orally. Compounded capsules or tablets allow for precise dosing at concentrations below what is practical with commercially available pharmaceutical preparations. A notable and expected side effect is the transient discoloration of urine and sometimes saliva to blue or green, which is harmless and resolves as the compound is cleared. Users should be informed of this before initiating so it is not mistaken for a clinical concern.

Methylene blue may be a consideration for adults working with a provider interested in mitochondrial support, cognitive wellness, or longevity-focused protocols that target cellular energy pathways. It is not appropriate for individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, in whom it can cause hemolytic anemia. It also carries meaningful drug-drug interaction risk with serotonergic medications -- including SSRIs, SNRIs, and MAOIs -- where it may contribute to serotonin syndrome, particularly at higher doses.

This product is a compounded prescription and is dispensed only after a licensed provider reviews your health history and medication list. It is not FDA-approved for longevity, cognitive, or mitochondrial health indications. The human evidence base for low-dose methylene blue in wellness contexts is primarily from small studies and preclinical research; this is an emerging area of investigation.